ISIS EIF4ERx

Drug Profile

ISIS EIF4ERx

Alternative Names: eIF-4E ASO; ISIS 183750; ISIS-EIF4ERx; LY 2275796; LY2275796 sodium

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Eukaryotic initiation factor 4E inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 14 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease) in USA (IV)
  • 14 Aug 2015 No recent reports on development identified - Phase-II for Prostate cancer (Combination therapy) in USA (IV)
  • 24 Oct 2008 Interim adverse events, pharmacokinetics, and pharmacodynamics data from a phase I trial in solid tumours presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top